Philips Launches Azurion With FlexArm


January 17, 2019—Royal Philips announced the launch of Azurion with FlexArm for image-guided procedures. The Philips Azurion 7 C20 with FlexArm, which has received CE Mark approval and FDA 510(k) clearance, provides quick and easy visualization of critical anatomy to identify changes to the patient during the complex interventional procedure.

According to the company, Azurion with FlexArm is powered by a smart kinematic engine, the system moves on eight different axes, all controlled with its single Axsys controller. The system's design provides exceptional flexibility and intuitive control and includes innovations that make it easier for the clinician to perform imaging across the whole patient in both two and three dimensions.

As the clinician moves the system, the image beam automatically maintains alignment with the patient, allowing more consistent visualization and enabling them to keep their focus on the treatment.

In the company's announcement, Barry T. Katzen, MD, commented, “With FlexArm, Philips’ engineers have overcome near-impossible geometric and mechanical barriers to enable clinicians to achieve clinical excellence in image-guided therapy. FlexArm enables us to dramatically optimize procedures around the patient: we can get the optimal view of what’s going on inside the patient without encumbering all of the clinicians that are working around the table. The result is an innovation that’s not only clinically important but also very simple and intuitive to use—a critical factor in the heat of a complex procedure.”


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.